Table 3.
Variable | Univariable analysis | Multivariate analysis | ||||||
---|---|---|---|---|---|---|---|---|
HR | 95% CI | p value | HR | 95% CI | p value | |||
Age | 0.82 | 0.54–1.25 | 0.352 | |||||
Histological subtype | 0.82 | 0.50–1.35 | 0.44 | |||||
Grade | 2.02 | 1.19–3.41 | 0.009 | * | 1.88 | 1.13–3.13 | 0.015 | * |
FIGO stage | 2.63 | 1.29–5.34 | 0.008 | * | 2.27 | 1.16–4.46 | 0.017 | * |
Lymph node metastasis | 1.92 | 1.19–3.10 | 0.008 | * | 1.95 | 1.20–3.15 | 0.007 | * |
Serum CA125 | 0.98 | 0.62–1.55 | 0.925 | |||||
Ascites | 0.70 | 0.45–1.08 | 0.11 | |||||
HOXD-AS1 expression | 1.94 | 1.22–3.06 | 0.005 | * | 1.92 | 1.23–3.00 | 0.004 | * |
aCox hazard model
b200 patients with full clinical information including age, FIGO stage,histological type,type of chemotherapy and type of surgery.HR,hazard ratio;CI,confidence interval;FIGO, International Federation of Gynecology and Obstetrics; CA125, carbohydrate antigen 125; HOXD-AS1, HOXD Cluster Antisense RNA 1